<DOC>
	<DOCNO>NCT01208324</DOCNO>
	<brief_summary>The aim study examine effect estrogen serotonin cognition , emotional processing , brain activation . The investigator study effect acute tryptophan ( TRP ) depletion cognition mood healthy menopausal woman estrogen replacement treatment ( ERT ) . Using functional magnetic resonance imaging ( fMRI ) , investigator identify difference brain activation memory task without TRP depletion estrogen therapy order determine brain region cognitive function affect manipulation .</brief_summary>
	<brief_title>Estrogen Serotonin Changing Brain Chemistry</brief_title>
	<detailed_description>The overarch purpose study understand individual interactive effect hormone estrogen neurotransmitter serotonin certain aspect cognition brain activation menopausal woman age 48 60 year . Women undergo cognitive test fMRI session 6 week either estrogen placebo administration . We recruit woman across first 10 year since last menstrual period investigator gather information regard potential impact time since menopause outcomes interest . We anticipate finding study help scientist clinician refine use estrogen therapy menopausal woman . In addition , role serotonin utmost importance maintenance healthy cognition , data aid future drug development preserve health cognition and/or treat dementia serotonin important factor . This proposal novel timely result study likely provide information critical on-going discussion regard risk benefit ET use menopausal woman .</detailed_description>
	<mesh_term>Serotonin</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Key Women age 48 60 ( time enrollment ) eligible study : 1 . Have history major depressive disorder , generalize anxiety disorder , panic disorder within last three year accord Structured Clinical Interview DSMIV ( Diagnostic Statistical Manual ) Axis I Disorders ( SCIDNP ) ( First et al. , 1995 ) , history major depressive disorder , generalize anxiety disorder , panic disorder great 3 year ago , resolve accord Structured Clinical Interview DSMIV Axis I Disorders ( SCIDNP ) ( First et al. , 1995 ) ; 2 . Have substance abuse disorder ( include alcohol , prescription , illicit substance ) within last three year accord Structured Clinical Interview DSMIV Axis I Disorders ( SCIDNP ) ( First et al. , 1995 ) ; 3 . Subject history substance abuse disorder ( include alcohol , prescription , illicit substance ) &gt; 3 year ago period abuse last 5 year accord Structured Clinical Interview DSMIV Axis I Disorders ( SCIDNP ) ( First et al. , 1995 ) ; 4 . No firstdegree relative ( exclude child ) know psychotic disorder bipolar disorder per patient report . Psychotic disorder include schizophrenia , schizoaffective disorder , psychotic disorder ; 5 . Have take hormonal contraceptive , ET ( estrogen therapy ) HT ( hormone therapy ) least 3 month per selfreport ; 6 . Are within 10 year 11 month LMP ( last menstrual period ) per selfreport ; 7 . Have follicular stimulate hormone level ( FSH ) &gt; 30 IU/ml per hormone test result ; woman FSH 30 option undergo additional blood draw 39 month follow initial blood draw ( see note 2 ) ; 8 . Are able give write informed consent ; 9 . Provide write documentation normal mammogram PAP smear ( Papanicolaou test ) within recommend timeframe defined American College Obstetricians Gynecologists ( ACOG ) please visit website current recommendation ; 10 . Must clear urine toxicology screen upon recruitment ; 11 . Are fluent write spoken English ; 12 . Are righthanded . Key Exclusion Criteria 1 . Currently smoke 10 cigarettes/day self report ; 2 . History clinical CVD ( cardiovascular disease ) include myocardial infarction , angina , congestive heart failure ; 3 . History thromboembolic disease ( deep vein thrombosis pulmonary embolus ) ; 4 . History untreated ( cholecystectomy ) gallbladder disease per selfreport PE ; 5 . History triglyceridemia subject report ; 6 . Undiagnosed vaginal bleeding per selfreport ; 7 . History estrogen responsive cancer per selfreport ; 8 . Known hypercoagulable state ( thrombophilias ) per selfreport ; 9 . Severe lactose intolerance ( sham depletion require lactose/microcellulose administration ; mild moderate lactose intolerance acceptable ) ; Dr. Epperson make final decision whether individual 's lactose intolerance severe enough require exclusion ; 10 . Use estrogen progestincontaining medication phytoestrogen contain supplement ( e.g . soy concentrate extract ) within 3 month participation per selfreport ; food contain soy ( e.g . tofu , soy milk ) permissible ; estrogenbased localized treatment cream vaginal insert permissible , long say treatment effect systemic estrogen level ( woman use localized treatment must estrogen level similar woman study age menopause status ) . PI final decision enrollment ( see note 3 ) ; 11 . Have Mini Mental Status Score &lt; 25 ; 12 . Hamilton Depression Score &gt; 14 ; 13 . As per selfreport , take psychotropic medication within previous month , exception sleep aid participant willing forgo use study participation ; 14 . Have metallic implant per selfreport ; 15 . Are claustrophobic per selfreport ; 16 . Are pregnant ( pertains perimenopausal woman ) . Note 1 : In case participant full partial hysterectomy , time final menstrual period determine Dr. Epperson ( study PI ) one study MDs . In case final menstrual period establish , subject exclude study . Note 2 : Women undergo repeat FSH blood test enrol level &gt; 30 . Women require repeat admission procedure unless report experience life event would impact mental physical health wellbeing . The PI make final determination regarding , , screen procedure need repeat . Note 3 : Women localize estrogen treatment show elevated systemic estrogen level enrol . Instead , need discontinue use 1 month estrogen level retested additional blood draw . PI final decision regard eligibility .</criteria>
	<gender>Female</gender>
	<minimum_age>48 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cognitive difficulty</keyword>
	<keyword>memory impairment</keyword>
	<keyword>mood change</keyword>
	<keyword>brain activation</keyword>
</DOC>